Daniel DiPietro
Gründer bei Modis Therapeutics, Inc.
Profil
Mr. Dan D.
DiPietro is Founding Partner at Aceras BioMedical LLC.
Mr. DiPietro has a wealth of biotech investment and biomedical research experience.
Prior to founding Aceras in May 2008, he was a co-founder of Bioenvision Inc, an oncology company which gained approval for its lead drug and was acquired by Genzyme Corp in 2007.
He was responsible for over $300M in direct investments in emerging public biotechnology companies as a Managing Director at SCO Capital Partners, a life sciences merchant bank.
He is also a co-founder of several biotechnology companies, while being a Managing Director at Paramount BioSciences.
He has three years of hedge fund analytical experience at Promed Management and Paramount BioCapital.
He also has five years basic biomedical research experience.
Mr. DiPietro received his B.A.
in Political Science from The State University of New York at Stony Brook and his M.A.
in Biological Sciences from Columbia University.
He was a Research Associate at Howard Hughes Medical Institute.
Aktive Positionen von Daniel DiPietro
| Unternehmen | Position | Beginn |
|---|---|---|
Paramount BioCapital, Inc.
 Paramount BioCapital, Inc. Investment ManagersFinance Paramount BioCapital, Inc. is an alternative investment manager. The private company is based in New York, NY and has subsidiaries in the United States. | Corporate Officer/Principal | 22.04.2009 |
Aceras BioMedical LLC
 Aceras BioMedical LLC Investment ManagersFinance Aceras BioMedical LLC (Aceras BioMedical) is a porivate equity/venture capital firm founded in 2008 by Peter barber, Matthew Wyckoff, and Daniel DiPietro. The firm is headquartered in New York, New York. | Gründer | 07.12.2009 |
Modis Therapeutics, Inc.
 Modis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Modis Therapeutics, Inc. is a biopharmaceutical company, which develops disease-modifying therapies for rare genetic diseases. Its product MT1621 is in clinical development for thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disease. The company was founded by Peter H. Barber and Daniel D. DiPietro in 2016 and is headquartered in Oakland, CA. | Gründer | 01.01.2016 |
| Brooklyn Conservatory of Music | Direktor/Vorstandsmitglied | 01.01.2017 |
Ehemalige bekannte Positionen von Daniel DiPietro
| Unternehmen | Position | Ende |
|---|---|---|
SCO Capital Partners LLC
 SCO Capital Partners LLC Investment ManagersFinance Founded in 1997, SCO Capital Partners LLC is a venture capital firm located in New York City. The firm is a subsidiary of SCO Financial Group LLC. | Direktor der Forschung - Eigenkapital | 22.07.2005 |
Howard Hughes Medical Institute, Inc.
 Howard Hughes Medical Institute, Inc. Investment Trusts/Mutual FundsMiscellaneous Howard Hughes Medical Institute, Inc. engages in the provision of biomedical research services and science education programs. It funds grants to both institutions and individuals in support of a wide range of science and research-related initiatives, including precollege and undergraduate science education, pre- and post-doctoral research fellowships, and international research activities. The company was founded by Howard R. Hughes in 1953 and is headquartered in Chevy Chase, MD. | Corporate Officer/Principal | - |
Mt. Cook Pharma, Inc.
 Mt. Cook Pharma, Inc. Pharmaceuticals: MajorHealth Technology Mt. Cook Pharma, Inc. provides treatment for urological diseases. It offers services to overactive bladder, lower urinary symptoms, and interstitial cystitis diseases. The company was headquartered in Princeton, NJ. | Direktor/Vorstandsmitglied | - |
Ausbildung von Daniel DiPietro
| The Trustees of Columbia University in The City of New York | Graduate Degree |
| The State University of New York | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
SCO Capital Partners LLC
SCO Capital Partners LLC Investment ManagersFinance Founded in 1997, SCO Capital Partners LLC is a venture capital firm located in New York City. The firm is a subsidiary of SCO Financial Group LLC. | Finance |
Paramount BioCapital, Inc.
Paramount BioCapital, Inc. Investment ManagersFinance Paramount BioCapital, Inc. is an alternative investment manager. The private company is based in New York, NY and has subsidiaries in the United States. | Finance |
Mt. Cook Pharma, Inc.
Mt. Cook Pharma, Inc. Pharmaceuticals: MajorHealth Technology Mt. Cook Pharma, Inc. provides treatment for urological diseases. It offers services to overactive bladder, lower urinary symptoms, and interstitial cystitis diseases. The company was headquartered in Princeton, NJ. | Health Technology |
Howard Hughes Medical Institute, Inc.
Howard Hughes Medical Institute, Inc. Investment Trusts/Mutual FundsMiscellaneous Howard Hughes Medical Institute, Inc. engages in the provision of biomedical research services and science education programs. It funds grants to both institutions and individuals in support of a wide range of science and research-related initiatives, including precollege and undergraduate science education, pre- and post-doctoral research fellowships, and international research activities. The company was founded by Howard R. Hughes in 1953 and is headquartered in Chevy Chase, MD. | Miscellaneous |
| Brooklyn Conservatory of Music | |
Aceras BioMedical LLC
Aceras BioMedical LLC Investment ManagersFinance Aceras BioMedical LLC (Aceras BioMedical) is a porivate equity/venture capital firm founded in 2008 by Peter barber, Matthew Wyckoff, and Daniel DiPietro. The firm is headquartered in New York, New York. | Finance |
Modis Therapeutics, Inc.
Modis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Modis Therapeutics, Inc. is a biopharmaceutical company, which develops disease-modifying therapies for rare genetic diseases. Its product MT1621 is in clinical development for thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disease. The company was founded by Peter H. Barber and Daniel D. DiPietro in 2016 and is headquartered in Oakland, CA. | Commercial Services |
